Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca Acquires Chinese Generics Firm
by Jean-François Tremblay
December 19, 2011
| A version of this story appeared in
Volume 89, Issue 51
AstraZeneca has agreed to buy Guangdong BeiKang Pharmaceutical, a producer of generic drugs in China’s Guangdong province. AstraZeneca says the acquisition provides a portfolio of injectable drugs used to treat infections. In recent years, multinational drug companies have been pushing to improve their position in the Chinese drug market, where rising affluence is increasing demand for brand-name medicines. In October, AstraZeneca announced plans to build a $200 million plant in Taizhou, Jiangsu province, that will produce injectable and oral drugs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter